CN101307085B - 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 - Google Patents
抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 Download PDFInfo
- Publication number
- CN101307085B CN101307085B CN2007100753608A CN200710075360A CN101307085B CN 101307085 B CN101307085 B CN 101307085B CN 2007100753608 A CN2007100753608 A CN 2007100753608A CN 200710075360 A CN200710075360 A CN 200710075360A CN 101307085 B CN101307085 B CN 101307085B
- Authority
- CN
- China
- Prior art keywords
- iron
- dna
- rna
- shrna
- slow virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 title claims description 23
- 102000004169 proteins and genes Human genes 0.000 title claims description 11
- 108020004459 Small interfering RNA Proteins 0.000 title description 20
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 title description 8
- 102000018511 hepcidin Human genes 0.000 title description 8
- 108060003558 hepcidin Proteins 0.000 title description 8
- 229940066919 hepcidin Drugs 0.000 title description 8
- 241000713666 Lentivirus Species 0.000 title description 2
- 230000006798 recombination Effects 0.000 title 1
- 238000005215 recombination Methods 0.000 title 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 136
- 229910052742 iron Inorganic materials 0.000 claims abstract description 68
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 56
- 239000004055 small Interfering RNA Substances 0.000 claims abstract description 48
- 241000700605 Viruses Species 0.000 claims abstract description 36
- 108091027967 Small hairpin RNA Proteins 0.000 claims abstract description 32
- 230000014509 gene expression Effects 0.000 claims abstract description 26
- 108020004414 DNA Proteins 0.000 claims description 30
- 238000012546 transfer Methods 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 108091033380 Coding strand Proteins 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 208000016286 Iron metabolism disease Diseases 0.000 claims description 5
- 230000002779 inactivation Effects 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 abstract description 15
- 108020004999 messenger RNA Proteins 0.000 abstract description 14
- 230000010438 iron metabolism Effects 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 6
- 108091006104 gene-regulatory proteins Proteins 0.000 abstract 3
- 102000034356 gene-regulatory proteins Human genes 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 29
- 108091030071 RNAI Proteins 0.000 description 28
- 102100022816 Hemojuvelin Human genes 0.000 description 19
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 10
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108060004795 Methyltransferase Proteins 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 101710099377 Protein argonaute 2 Proteins 0.000 description 4
- 102100034207 Protein argonaute-2 Human genes 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102000008682 Argonaute Proteins Human genes 0.000 description 2
- 108010088141 Argonaute Proteins Proteins 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000000213 Hemojuvelin Human genes 0.000 description 1
- 108050008605 Hemojuvelin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 101100512783 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MEH1 gene Proteins 0.000 description 1
- 206010041047 Slow virus infection Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100032008 Solute carrier family 40 member 1 Human genes 0.000 description 1
- 101710111423 Solute carrier family 40 member 1 Proteins 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000002512 suppressor factor Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100753608A CN101307085B (zh) | 2007-08-01 | 2007-08-01 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100753608A CN101307085B (zh) | 2007-08-01 | 2007-08-01 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101307085A CN101307085A (zh) | 2008-11-19 |
CN101307085B true CN101307085B (zh) | 2012-06-13 |
Family
ID=40123786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100753608A Expired - Fee Related CN101307085B (zh) | 2007-08-01 | 2007-08-01 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101307085B (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101875931B (zh) * | 2009-04-28 | 2013-06-12 | 香港理工大学深圳研究院 | 抑制人膜铁转运蛋白辅助蛋白基因表达的siRNA重组慢病毒及应用 |
AU2012251919B2 (en) * | 2011-01-19 | 2016-12-15 | Ferrumax Pharmaceuticals, Inc. | Compositions for regulating iron homeostasis and methods of using same |
CN103169948B (zh) * | 2011-12-22 | 2019-10-25 | 中国科学院上海生命科学研究院 | 铁调素调节蛋白对机体免疫的调节作用及其应用 |
SG11201507226YA (en) | 2013-03-15 | 2015-10-29 | Protagonist Therapeutics Inc | Hepcidin analogues and uses therof |
CN103251932A (zh) * | 2013-04-17 | 2013-08-21 | 钱忠明 | 铁调素在制备铁相关神经退行性疾病药物中的应用 |
ES2890600T3 (es) | 2014-05-16 | 2022-01-20 | Protagonist Therapeutics Inc | Péptidos de tioéter antagonistas de integrina alfa4beta7 |
AU2015279571A1 (en) * | 2014-06-27 | 2017-02-02 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
BR112017001010A2 (pt) | 2014-07-17 | 2017-11-14 | Protagonist Therapeutics Inc | inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais |
SG11201702553RA (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics Inc | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
MX2022000397A (es) | 2019-07-10 | 2022-04-25 | Protagonist Therapeutics Inc | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
CN118005736A (zh) | 2020-01-15 | 2024-05-10 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
CN111647083B (zh) * | 2020-04-28 | 2022-06-03 | 武汉百杰康生物科技有限公司 | 一种重组小鼠抗人血幼素单克隆抗体、制备方法和应用 |
AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
-
2007
- 2007-08-01 CN CN2007100753608A patent/CN101307085B/zh not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
lan lin等.Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin.《Blood》.2005,第106卷(第8期),2884-2889. * |
Also Published As
Publication number | Publication date |
---|---|
CN101307085A (zh) | 2008-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101307085B (zh) | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 | |
US8962583B2 (en) | Treatment of inflammatory diseases using miR-124 | |
CN108368487A (zh) | 核酸的外泌体包装 | |
CN101842381A (zh) | 作为微小rna模拟物或抑制剂的不对称rna双链体的组合物 | |
Israsena et al. | Inhibition of rabies virus replication by multiple artificial microRNAs | |
CN114134211B (zh) | Usp30基因作为靶点在抑制塞内卡谷病毒复制中的应用 | |
US20090136544A1 (en) | Interfering RNAs Targeting the Morbillivirus Nucleoprotein Gene | |
CN103667286A (zh) | 日本血吸虫PGMRC2基因的siRNA及其应用 | |
CN105200059B (zh) | 靶向抑制小鼠UCP2基因表达的siRNA及其表达载体的构建 | |
CN103740722A (zh) | 抑制视网膜色素上皮细胞凋亡的shRNA及其应用 | |
CN110129319B (zh) | 一种PRALR的siRNA及其用途 | |
CN101538569B (zh) | 抑制人dmt1蛋白的rna、重组体及应用 | |
CN101921763B (zh) | 抑制PAR-1基因表达的siRNA及其应用 | |
CN104745635B (zh) | 一种沉默df-1细胞系中oasl基因的方法 | |
WO2023145884A1 (ja) | SARS-CoV-2由来ポリヌクレオチド及びその使用 | |
CN114574486B (zh) | 作用于OPLAH的siRNA、DNA及构建物和应用 | |
CN103667431B (zh) | 一种人ccch型锌指蛋白表达基因的用途及其相关药物 | |
CN103103189A (zh) | 过表达单一MicroRNA成熟体序列的新方法 | |
CN101875931B (zh) | 抑制人膜铁转运蛋白辅助蛋白基因表达的siRNA重组慢病毒及应用 | |
CN102604994B (zh) | 一种针对flg基因rna干扰的重组慢病毒载体及其制备 | |
CN101538568B (zh) | 抑制人膜铁转运蛋白的rna、重组体及其应用 | |
CN116622652A (zh) | 用于神经母瘤基因治疗的慢病毒及其制备方法和应用 | |
CN101532013A (zh) | 抑制人铁调素的rna、重组体及应用 | |
CN105147714A (zh) | 小分子RNA的应用及Rho激酶抑制剂 | |
CN111518804A (zh) | 一种环状RNA circRalgapa1及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HONG KONG POLYTECHNIC UNIVERSITY SHENZHEN INSTITUT Free format text: FORMER OWNER: QIAN ZHONGMING Effective date: 20100108 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20100108 Address after: A216 room, Shenzhen Virtual University Park, Nanshan District Science Park, Guangdong, Shenzhen Province, China: 518057 Applicant after: Shenzhen Inst., Hongkong Science &. Engineering Univ. Address before: Postal code of R2-A6 building, Nanshan District science and Technology Park, Shenzhen, Guangdong, China: 518057 Applicant before: Qian Zhong Ming Co-applicant before: Ge Xiaohu Co-applicant before: Ke Ya Co-applicant before: Wang Chengyuan |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120613 Termination date: 20140801 |
|
EXPY | Termination of patent right or utility model |